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ABSTRACT 
 
Roberts, Erin. M.S. Department of Microbiology and Immunology, Wright State 
University, 2017. Cytokine expression, cytoskeleton organization, and viability of SIM-
A9 microglia exposed to Staphylococcus aureus-derived lipoteichoic acid and 
peptidoglycan. 
 
In these experiments, SIM-A9 microglia were exposed to Staphylococcus aureus cell 
wall components lipoteichoic acid (LTA) and peptidoglycan (PGN) at a concentration of 
5 g/mL for six, twelve, eighteen, and twenty-four hours and the cytokine expression, 
cytoskeleton organization, and cell viability of the cells were observed. Following LTA 
and PGN exposure, TNF- secretion increased at each time interval and was highest 
observed at 24 hours. No significant IL-10 secretion was detected. Over the 24 hour 
period, cell viability and cytotoxicity of LTA and PGN treatment groups were not 
significantly different from the control, indicating the observed inflammatory cytokine 
response was not due to cell death. These data suggest that LTA and PGN play a 
predominantly inflammatory role in the first twenty-four hours of S. aureus CNS 
infection. 
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INTRODUCTION 
Staphylococcus aureus (S. aureus) is a gram positive bacterium found in the 
commensal flora of the skin and nasal cavities of 60% of humans (Fournier & Philpott, 
2005). However, S. aureus can also be a harmful opportunistic pathogen, commonly 
presented clinically as skin and soft tissue infections (Fournier & Philpott, 2005). While 
less frequent, S. aureus can infect the central nervous system (CNS) as brain abscesses or 
meningitis, particularly following neurosurgeries repairing brain and spinal cord trauma 
or inserting a cerebrospinal fluid shunt (Kumari et al., 2015). Bacterial meningitis caused 
by S. aureus has a mortality rate as high as 36% (Wang et al., 2005).  In addition, S. 
aureus is the second highest causative agent of CNS shunt infections, accounting for over 
20% of cases (Lee et al., 2012; Schoenbaum, Gardener, & Shillito, 1975). The bacterium 
is known to form biofilms on shunt surfaces which confer antibiotic resistance and are 
associated with increased mortality and risk of seizure (Snowden et al., 2013).  
 Common to many gram positives, the outer wall of S. aureus is chiefly comprised 
of two components: lipoteichoic acid (LTA) and peptidoglycan (PGN) (Fournier & 
Philpott, 2005). Pattern recognition receptors (PRRs) on the surface and in the cytosol of 
innate immune cells recognize these components as pathogen-associated molecular 
patterns (PAMPs) and initiate the inflammatory immune response to combat the infection 
(Kieser & Kagan, 2017). These PRRs include toll-like receptors (TLRs) and nucleotide-
binding oligomerization domain-like receptors (NOD-like receptors or NLRs).  
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During infection, S. aureus employs a number of virulence factors to evade the 
immune response. C5a is a powerful component of complement with many inflammatory 
functions including the recruitment of neutrophils to the site of infection (Nizet, 2007). S. 
aureus can secrete chemotaxis inhibitory protein of staphylococci (CHIPS) that bind the 
C5a receptor on neutrophils and prevent recruitment (Demaster et al., 2002). Secretion of 
extracellular adherence proteins by S. aureus inhibits intracellular adherence molecule-1 
(ICAM-1), the receptor that allows leukocytes to leave the blood stream and penetrate 
infected tissues (Haggar et al., 2004). In addition, many S. aureus strains release toxins 
that puncture the membrane of leukocytes and super antigens that cause massive cytokine 
storms, resulting in fever, rash, and multiple-organ failure (Foster, 2005).  
S. aureus also employs mechanisms to resist phagocytosis and digestion by 
macrophages and neutrophils. Neutrophils are known to deploy neutrophil extracellular 
traps (NETs) made of chromatin and histones that ensnare pathogens while the neutrophil 
secretes anti-microbial enzymes; S. aureus can produce enzymes that degrade these NETs 
(Brinkmann et al., 2004; Nizet, 2007). Furthermore, S. aureus produces catalases and 
superoxide dismutases to neutralize the oxidative burst once phagocytized and previous 
studies document the bacterium’s ability to escape the phagosome and survive in the 
cytoplasm of neutrophils and macrophages (Gresham et al., 2000; Mandell, 1975).  
 In the CNS, microglia are among the most important innate immune cells. The 
resident macrophages of the CNS, microglia digest pathogens such as S. aureus through 
phagocytosis and release inflammatory cytokines like tumor necrosis factor- (TNF-) to 
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stimulate the immune response (Hoogland et al., 2015). While functioning as the first line 
of defense in CNS infections, microglia also present digested PAMPs to the adaptive 
immune system to stimulate antibody production (Shemer & Jung, 2015). Microglia also 
play an anti-inflammatory role in wound healing by clearing necrotic debris by 
phagocytosis, secreting anti-inflammatory cytokines such as interleukin-10 (IL-10), and 
secreting growth factors to promote angiogenesis (Stroncek & Reichert, 2008).   
We investigated the interactions between S. aureus antigens and microglia during 
CNS infection and the subsequent innate immune response. We also wanted to compare 
directly any possible differences in response to S. aureus-derived LTA and PGN. To 
these ends we treated SIM-A9 murine microglia with either S. aureus-derived LTA or 
PGN and examined the cytokine expression, cytoskeleton organization, and cell viability 
at six, twelve, eighteen, and twenty-four hours after treatment. The SIM-A9 cell line was 
chosen because previous studies report SIM-A9 to behave more similarly to primary 
microglia than virally transformed microglial cell cultures (Nagamoto-Combs, Kulas, & 
Combs, 2014). The cell line arose from spontaneous immortalization of primary 
microglia obtained from C57BL/6 mice (Nagamoto-Combs et al., 2014). Nagamoto-
Combs and colleagues (2014) demonstrated SIM-A9 microglia are capable of switching 
between inflammatory and anti-inflammatory phenotypes by stimulation with LPS and 
IL-4, respectively. The researchers also established the phagocytic abilities of SIM-A9 
cells via the observed uptake of fluorescently labeled bacterial antigens (Nagamoto-
Combs et al., 2014). 
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Due to the limited regenerative abilities of neuronal tissue, cell death in the CNS 
resulting from bacterial inflammation is especially devastating. With increasing 
emergence of antibiotic-resistant strains of the bacterium such as methicillin-resistant S. 
aureus (MRSA) and vancomycin-resistant S. aureus (VRSA), better understanding the 
immune response of microglia to S. aureus CNS infection will be important for the 
development of novel drugs and therapies.  
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LITERATURE REVIEW 
Staphylococcus aureus 
 S. aureus is a gram-positive bacterium with a thick cell wall surrounding the 
cellular membrane (De Kimpe, Kengatharan, Thiemermann, & Vane, 1995). PGN is the 
principal member of the cell wall and is composed of repeating N-acetyl glucosamine 
(NAG) and N-acetyl muramic acid (NAM) subunits bound by peptide links (Kumar et al., 
2012). LTA is an amphiphilic glycolipid bound to the cellular membrane and protrudes 
through the PGN layers of the cell wall as seen in Figure 1 (Schröder et al., 2003). PRRs 
on the surface and in the cytosol of microglia recognize these two components as PAMPs 
and initiate the immune response. 
 
Lipoteichoic Acid 
 LTA induces the production of TNF-, IL-10, and chemoattractants in innate 
immune cells (Von Aulock et al., 2004). In macrophages like microglia, TLR2 forms a 
heterodimer with either TLR1 or TLR6 to bind LTA (Takeuchi et al., 2001, 2002) 
(Figure 2). This heterodimer is bound by either cluster of differentiation (CD) 14 or 
CD36 to enhance the recognition of LTA (Hoebe et al., 2005; Horng, Barton, Flavell, & 
Medzhitov, 2002). LTA recognition activates the signaling molecules MYD88 (myeloid 
differentiation factor 88) and TIRAP (toll-IL-1R domain-containing adapter protein) 
which in turn activate TRAF6 (TNF receptor-associated factor 6) (Nakata et al., 2006; 
Takeuchi et al., 2000). The signal cascade activates transcription factor NF-B (nuclear 
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factor kappa B), which enters the nucleus to bind the DNA and upregulate the 
transcription of pro-inflammatory chemokines and cytokines such as TNF-.  
 Previous research examined the cytokine response of S. aureus-derived LTA 
using a modified human kidney cell line transfected with TLR2 (Von Aulock et al., 
2004). Researchers treated the transfected cells for 6 hours with LTA and compared 
cytokine production to cells treated with lipopolysaccharide (LPS), a cell wall component 
found in gram negative bacteria known to be a strong inducer of cytokines (Kusunoki et 
al., 1995; Von Aulock et al., 2004). LTA was a weak inducer of TNF- compared to 
LPS, but was an equally strong inducer of chemoattractants and IL-10, suggesting LTA 
plays a role in the formation of pus during infection by attracting neutrophils to the site of 
infection (Von Aulock et al., 2004). Other studies have shown LTA induces microglial 
production of iNOS (inducible nitric oxide species) and COX-2 (cyclooxygenase 2), 
enzymes commonly present in many CNS diseases and injuries (Huang et al., 2013). 
 
Peptidoglycan 
PGN comprises half of the thick outer cell wall seen in S. aureus and provides 
structural integrity to combat osmotic pressure (Boneca, 2005). It was originally believed 
PGN, like LTA, was recognized by TLR2, however more recent studies have highlighted 
NOD2 as the primary PRR (Chamaillard et al., 2003; Stephen E. Girardin et al., 2003). 
As seen in Figure 3, microglia are able to engulf an entire S. aureus bacterium as well as 
individual PGN molecules secreted during bacterial replication. Digested or engulfed 
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PGN fragments containing MDP (muramic dipeptide) are sensed by NOD2 (Chamaillard 
et al., 2003; Girardin et al., 2003). MDP is present in virtually all types of bacterial PGN, 
suggesting NOD2 participates in general PGN surveillance (Girardin et al., 2003).  
Once activated, NOD-2 initiates the NF-B signaling cascade (Abbott, Wilkins, 
Asara, & Cantley, 2004). NOD2 recruits CARD12 (caspase recruitment domain-
containing protein 12) which in turn activates RICK (receptor-interacting 
serine/threonine kinase) (Inohara et al., 2003). RICK activation leads to the activation of 
NF-B, which is then able to enter the nucleus and upregulate the expression of 
inflammatory cytokines (Inohara et al., 2003). Similarly, NOD2/CARD12 also initiate the 
MAPK signaling cascade, allowing JNK (JUN N-terminal kinase) to enter the nucleus 
and promote the transcription of cytokines (Girardin et al., 2001). 
Kielian and colleagues (2002) compared the pro-inflammatory cytokine and 
chemokine expression of microglia stimulated with S. aureus PGN and whole heat-killed 
bacteria. They reported PGN to be a potent inducer of TNF- as well as pro-
inflammatory chemokines (Kielian, Mayes, & Kielian, 2002). PGN is also a powerful 
inducer of C5a, a strong chemoattractant for neutrophils (Schmeling et al., 1979).  
 
Microglia 
 Microglia are the resident macrophages of the CNS and function as the first line 
of defense against CNS infections. Microglia share many similarities with macrophages 
active in the periphery, however there are several key differences. Unlike macrophages, 
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microglia become resident very quickly; microglial precursors arise from yolk-sac 
progenitors and colonize the brain during embryonic development (Kierdorf et al., 2013). 
Macrophages and dendritic cells have a high turnover rate and are continuously 
replenished from myeloid progenitors in the bone marrow (Bain et al., 2014). Microglia 
instead rapidly proliferate during infection to maintain their numbers and undergo 
apoptosis to return to normal levels once the infection is cleared (Ginhoux & Prinz, 
2015). Responsible for homeostasis in the brain, microglia are also much more tightly 
regulated than macrophages to limit neuronal damage by inflammation (Aloisi et al., 
1999). 
The activation states and function of microglia are separated into three general 
categories: M0, M1, and M2 (Figure 4). Throughout its lifespan a microglial cell 
frequently switches between these activation states in response to environmental stimuli 
(Stout et al., 2005). Inactivated microglia are referred to as M0. In this resting state, M0 
microglia constantly extend and retract their processes as they patrol the brain and spinal 
cord, searching for signals of pathogens, inflammation, or tissue damage (Nimmerjahn, 
Kirchhoff, & Helmchen, 2005).  
 M1 microglia are characterized by the inflammatory phenotype. Activation occurs 
in recognition of PAMPs or inflammatory cytokines such as interferon-gamma (IFN-) 
and TNF- (Brown & Vilalta, 2015).  These microglia kill invading pathogens by 
phagocytosis and secrete inflammatory cytokines and chemokines to stimulate the innate 
immune response (Brown & Vilalta, 2015).  
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 Anti-inflammatory signals such as IL-4, IL-10, and IL-13 activate M2 microglia 
(Gerber & Mosser, 2001). These cells function in regulating the inflammatory response. 
While inflammation is critical to clear infections, sustained inflammation causes 
significant harm to tissues. M2 macrophages secrete IL-10 and anti-inflammatory 
cytokines to balance the inflammation and limit tissue damage. M2 macrophages also 
assist in wound healing by clearing necrotic tissue by phagocytosis and secreting 
cytokines like IL-4 to promote tissue repair (Kreider et al., 2007). 
 
Cytoskeleton 
 The cellular cytoskeleton is composed of three types of filaments: microtubules, 
microfilaments, and intermediate filaments. Working together, these filaments organize 
the cell organelles and compartments, coordinate cell motility, and enable changes in cell 
morphology (Fletcher & Mullins, 2010).  
Microtubules are the largest filaments and are comprised of alpha and beta 
subunits of tubulin. Microtubules form tubes comprised of /β-tubulin and provide the 
scaffolding that determines cell shape (Rodionov et al., 1993). Microtubules also provide 
the tracks on which motor proteins, such as kinesins and dyneins, travel throughout the 
cell and provide intracellular transport. Arrangements of microtubules in flagella and 
pseudopoda allow for cellular motility. One of the primary means of attack by microglia 
is phagocytosis of foreign pathogens. During phagocytosis, the extension of microtubules 
allow the cell to engulf invading pathogens (Harrison & Grinstein, 2002). Motor proteins 
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travel along the microtubules and mediate the fusion of endosomes and lysosomes with 
the phagosome, resulting in the digestion of phagocytized pathogens (Harrison & 
Grinstein, 2002). 
 Microfilaments are smaller in size than microtubules and are chiefly comprised of 
the compound actin. Microfilaments also play a role in cell motility, such as muscle 
contraction and cytokinesis (Theriot & Mitchison, 1991). In microglia, microfilament 
organization changes in response to chemo-attractants to allow the cells to migrate to the 
site of infection (Cross & Woodroofe, 1999). Actin filaments also play a role in 
phagocytosis, congregating around the phagocytic cup (Harrison & Grinstein, 2002). 
Both microtubules and microfilaments are highly dynamic structures that are rapidly built 
and dismantled in response to the extracellular environment and the needs of the cell 
(Cassimzeris, Pryer, & Salmon, 1988). 
 
 11 
HYPOTHESIS 
 
In vitro exposure of SIM-A9 microglia to S. aureus-derived lipoteichoic acid and 
peptidoglycan will cause pro-inflammatory cytokine secretion to increase over the 
twenty-four hour period and the cytoskeleton arrangement will exhibit a rounded 
morphology as a result. Anti-inflammatory cytokine secretion will decrease over time. 
Lastly, cell viability during the first twenty-four hours will not decrease over time nor 
will cytotoxicity increase because S. aureus cell wall components do not contain toxins 
and are not known to induce apoptosis. 
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MATERIALS AND METHODS 
Cell Culture 
The SIM-A9 (ATCC® CRL-3265) murine microglia cell line was originally obtained 
from spontaneously immortalized microglia taken from C57BL/6 mice and have an 
adherent cell growth pattern. For these experiments, SIM-A9 microglia were cultured in 
vented Iolite flasks (Fisher Scientific, Pittsburgh, PA) in a medium comprised of 
Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 (DMEM:F12), 5% heat-
inactivated horse serum, 10% heat-inactivated fetal bovine serum, and 10 mM HEPES 
buffer and incubated at 37C in 5% carbon dioxide and 100% humidity. Cells were 
passaged three or four times a week when the confluency of the culture was at least 70%. 
Confluency was measured by visual observation of the cells in the flask. The adherent 
cells were split using a splitting solution comprised of Dulbecco's phosphate buffered 
saline (D-PBS), 0.5% glucose solution, 0.2% EGTA, and 1% EDTA. Macrophage cell 
type was confirmed by immunofluorescent staining of CD11b, an integrin expressed on 
the surface of macrophages and microglia involved in cell migration (Figure 5). 
 
Cell Counting 
To count the number of viable cells, cells were split from the flask and suspended in 
DMEM:F12 culture medium. From this cell suspension, 10 L was mixed with 20 L 
trypan blue (Fisher Scientific, Pittsburgh, PA) and 10 L of this mixture was mounted 
onto a hemocytometer. Mounted cells were viewed under 10X magnification and the 
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number of dead and living cells were recorded; dead cells took up the stain and appeared 
blue and living cells remained transparent. The total number of viable cells in suspension 
were calculated as follows: 
 
Total Viable Cells =  
Number of cells in five squares
5
 ×  25 ×  2 ×  10,000 
Equation 1: Equation used to calculate concentration of viable cells 
 
Experimental Treatments 
Experiments were performed by applying 5 g/mL S. aureus-derived LTA or PGN 
(Invivogen, San Diego, CA) to cell cultures for six, twelve, eighteen, or twenty-four 
hours. For inflammatory and anti-inflammatory positive controls, 1 g/mL Escherichia 
coli-derived LPS and 100 ng/mL IL-10 were applied, respectively. Experimental 
treatments are summarized in Table 1.  
Treatment Concentration Source, Catalog 
Negative Media only 
 
M2 Control: IL-10 100 ng/mL Thermo-Fischer Scientific, RMIL105 
M1 Control: E. coli LPS 1 μg/mL Sigma-Aldritch, LPS25 
S. aureus LTA 5 μg/mL Invivogen, tlrl-slta 
S. aureus PGN 5 μg/mL Invivogen, tlrl-pgns2 
 Table 1: Treatments used in these experiments 
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ELISA 
Our lab previously reported SIM-A9 microglia to be auto-fluorescent and thus ELISA 
was preferable to flow cytometry for analysis of cytokine expression (Evdokiou, 2017). 
Each well of a 24-well plate (Corning Inc., Corning, NY) was seeded with 10,000 cells in 
1 mL DMEM:F12 culture media and incubated overnight at 36C, 5% carbon dioxide, 
and 100% humidity to allow cells to adhere. The medium was then aspirated and cells 
were treated with appropriate stimulus (Table 1) in a total volume of 1 mL and incubated 
at 36C, 5% carbon dioxide, and 100% humidity for six, twelve, eighteen, or twenty-four 
hours. At each time interval, supernatants were collected in a 2mL tube and any 
suspended cells were pelleted by centrifugation. Supernatants were then carefully 
transferred to a new tube and stored at -80C until plated for ELISA. This process was 
performed in triplicate for each sample at each time point. 
 
Mouse IL-10 and TNF alpha ELISA Ready SET Go kits (Affymetrix, Santa Clara, CA) 
were used to quantify IL-10 and TNF- secretion. Using a Corning 96-well plate 
(Corning, NY), 100 L capture antibody in 1X coating buffer was added to each well and 
incubated overnight at 4C. The plate was washed three times with a PBS and Tween-20 
wash buffer and blocked with 200 L 1X diluent for 1 hour. The plate was again washed 
with the buffer and 100 L standards and supernatants were added to each well and 
incubated overnight at 4C. Per manufacturer’s instruction, the top concentration for IL-
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10 and TNF- standard curves were 4000 pg/mL and 1000 pg/mL, respectively, and 
twofold dilutions were created for a total of eight points on the standard curve. Standards 
were plated in duplicate and supernatants were plated in triplicate. The plate was washed 
with wash buffer three times and 100 L detection antibody in 1X diluent was added to 
each well and incubated at room temperature for 1 hour. Following another wash, 100 L 
Avidin-Horseradish Peroxidase (HRP) enzyme in 1X diluent was added to each well and 
incubated at room temp for 30 minutes. The wash step was repeated five times and 100 
L of 1X TMB substrate solution was added to each well and incubated at room 
temperature for 15 minutes. After 15 minutes 50 L of 1M phosphoric acid was added to 
each well to stop the reaction. The plate was read by a SpectraMax Plus 384 Microplate 
Reader at 450 nm using SoftMax Pro 4.8 software (Molecular Devices LLC, San 
Francisco, CA). Any sample with a negative optical density (OD) was interpreted as 
below the detectable limit of the standard curve and was recorded as a zero for these 
experiments. Data were reported as the mean  standard error of the mean (SEM). 
Statistical significance was determined by one-way analysis of variance (ANOVA) with 
SigmaPlot 13.0 software (Systat Software Inc., San Jose, CA). 
 
Immunofluorescent Staining 
Each well of a 12-well chamber slide (Ibidi USA, Fitchburg, WI) was seeded with 5,000 
cells in 250 L DMEM:F12 media and incubated overnight at 36C, 5% carbon dioxide, 
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and 100% humidity to allow cells to adhere. The media was then aspirated and 
experimental treatments were applied (Table 1). Slides were then incubated at 36C, 5% 
carbon dioxide, and 100% humidity for six, twelve, eighteen, or twenty-four hours. 
Following incubation, the medium was aspirated and the slides were washed three times 
with 200 L 1X PBS. Cells were fixed with 100 L 4% paraformaldehyde at room 
temperature for 15 minutes. Wells were washed three times with 200 L 1X PBS and 
then permeabilized with 100 L 0.2% Triton X100 at room temperature for 10 minutes. 
Following another three washes with 200 L 1X PBS, the cells were blocked with 150 
L blocking buffer (PBS, 3% BSA, 5% goat serum, 0.05% Tween-20) for 30 minutes at 
room temperature. The following table summarizes the antibodies and stains used in 
these experiments: 
 
Antibody/Stain Dilution Company 
α/β –Tubulin #2148                                                                                                   
(Primary Tubulin Antibody) 
1:50 Cell Signaling Technology, Danvers, MA 
Anti-Rabbit IgG (H+L), F(ab’)2 Fragment  
(Alexa Fluor 488 conjugate) 
(Secondary Tubulin antibody) 
1:250 Cell Signaling Technology, Danvers, MA 
Texas Red-Phalloidin                                                                              
(F-actin tag) 
1:300 Cell Signaling Technology, Danvers, MA 
CD11b Monoclonal Antibody (M1/70), 
Alexa Fluor 488 
(Macrophage marker) 
10 g/mL Invitrogen, Carlsbad, CA 
 Table 2: Antibodies and stains used in these experiments 
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The slides were washed three times with 200 L 1% BSA and 50 L of the primary 
tubulin antibody were applied. The slides were incubated overnight at 4C. The following 
day, the primary antibody was aspirated and slides were washed three times with 200 L 
1% BSA. From this point, all further steps were completed in the dark. The fluorescent 
secondary tubulin antibody was applied to the cells in 50 L and incubated at room 
temperature for an hour. The antibody solution was aspirated, the slides were washed 
three times with 200 L 1% BSA, and 50 L of the fluorescent F-actin tag were applied 
for an hour at room temperature. The antibody solution was aspirated, the cells were 
washed three times with 200 L 1% BSA, and the slides were allowed to dry. Once dry, 
the coverslips were applied with several drops of VectaShield (Vector Laboratories, 
Burlingame, Ca) and allowed to harden for 20 minutes at room temperature. All slides at 
each time point were prepared in triplicate. Additionally, one slide was prepared in 
parallel staining for CD11b to confirm macrophage cell type (Figure 5). The slides were 
viewed with an Olympus Epi Fluorescent Spot Scope (Wright State University, 
Microscopy Core) at 465 nm for α/β-tubulin and 565 nm for Phalloidin-labeled F-actin 
and images were captured at 40X magnification. Images were selected under the 
subjective impression of about 25 cells in field.  The images were analyzed using ImageJ 
software (National Institutes of Health, Rockville, MD). The background noise was 
subtracted from each image and the mean fluorescent intensity was calculated and 
divided by the number of cells in the image. The data were reported as mean fluorescent 
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intensity/cell  SEM. Statistical significance was determined by one-way ANOVA with 
SigmaPlot 13.0 software.  
 
Percent Viability 
The wells of a 12-well plate (Corning Inc., Corning, NY) were each seeded with 100,000 
cells in 1 mL of DMEM:F12 media and incubated overnight at 36C, 5% carbon dioxide, 
and 100% humidity to allow cells to adhere. The medium was then aspirated and cells 
were stimulated with the appropriate treatment (Table 1) with a total volume of 1 mL for 
six, twelve, eighteen, or twenty-four hours at 36C, 5% carbon dioxide, and 100% 
humidity. At each time point, the supernatants of each well were collected in a 2 mL tube 
and any suspended cells were pelleted by centrifugation. For later use in the cytotoxicity 
assay, 500 L of supernatant was then transferred to a new 2 mL tube and stored at -
80C. The adherent cells were split from the 12-well plate with 500 L splitting solution, 
transferred to the 2 mL tube containing the pelleted cells, and the cells were re-suspended 
in the solution. From this 1 mL cell suspension, 10 L was mixed with 20 L trypan blue 
and 10 L of this mixture was loaded onto a hemocytometer. Under 10X magnification, 
the number of living and dead cells were counted and percent viability was then 
calculated as follows: 
Percent Viable Cells =  
Number of living cells
Number of living and dead cells
 ×  100 
Equation 2: Equation used to calculate percent viable cells 
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Data were reported as the mean  SEM. Statistical significance was determined by one-
way ANOVA with SigmaPlot 13.0 software. 
 
Lactose Dehydrogenase (LDH) Cytotoxicity Assay 
For this experiment, an LDH cytotoxicity kit was used (Caymen Chemical, Ann Arbor, 
MI). The controls for this experiment were seeded into a Corning 96-well plate in 
triplicate with 200,000 cells in 200 L of media as follows: 
 1 2 3 
A Background (200 L media only) “ “ 
B Max release (200 L cells + 20 L Triton) “ “ 
C Spontaneous Release (200 L cells) “ “ 
Table 3: Design of LDH cytotoxicity assay controls 
Controls were incubated at 36C, 5% carbon dioxide, and 100% humidity for six, twelve, 
eighteen, or twenty-four hours. At each time point, 100 L of supernatant from each 
control well was transferred to a new 96-well plate. Experimental supernatants collected 
from the percent viability assay were thawed and 100 L from each were also transferred 
to the new 96-well plate. To each well, 100 L of Reaction Solution was added and the 
plate was incubated at 36C, 5% carbon dioxide, and 100% humidity for 20 minutes, 
shaking the plate occasionally. After 20 minutes, the plate was read by a SpectraMax Plus 
384 Microplate Reader at 490 nm using SoftMax Pro 4.8 software. Per manufacturer’s 
instruction, ODs were converted to percent cytotoxicity by the following equation: 
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𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑐𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦 =  
𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 490 − 𝑆𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠 490
𝑀𝑎𝑥 490 − 𝑆𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠 490
 𝑥 100   
Equation 3: Equation used to convert OD to percent cytotoxicity. 
 
Data were reported as the mean  SEM. Statistical significance was determined by one-
way ANOVA with SigmaPlot 13.0 software. 
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RESULTS 
Differences in Cytokine Expression of Polarized Microglia 
SIM-A9 microglia treated with LPS as a positive inflammatory control over 24 hours 
consistently exhibited significantly higher TNF- secretion than control cells where 
TNF- secretion was undetectable (Figure 6). TNF- secretion induced by LPS 
appeared to peak at twelve hours, but there was no significant difference between any of 
the six hour time intervals (Figure 6). 
 
Microglia treated with IL-10 as an anti-inflammatory control secreted high levels of IL-
10 over 24 hours compared to negative control cells (Appendix Figure 1). IL-10 
secretion appeared to peak at six hours and decrease over 24 hours, but there was no 
significant difference between time points (Appendix Figure 1).  
 
LTA and PGN Inflammatory Cytokine Secretion over 24 Hours 
TNF- secretion was measured by ELISA. Over 24 hours, both LTA and PGN stimulated 
significantly higher TNF- production than the negative control and production 
progressively increased at each 6 hour interval, peaking at 24 hours for both components 
(Figure 7). Furthermore, PGN induced more TNF- secretion than LTA at all time 
intervals (Appendix Figure 2). 
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LTA and PGN Anti-Inflammatory Cytokine Secretion over 24 Hours. 
IL-10 secretion was measured by ELISA. IL-10 production by control cells appeared to 
peak at 100 ng/mL at six hours and decrease over 24 hours, but there was no significant 
difference observed between any of the time points (Appendix Figure 1). There was no 
detectable secretion of IL-10 among the negative control, LTA, or PGN experimental 
groups (Appendix Figure 1).  
 
Cytoskeleton Organization over 24 Hours 
Fluorescent images were selected under the subjective impression of an average 25 cells 
per field. The enlarged insets in Figure 8 and Figure 10 highlight the expected 
morphology of M1 and M2 activated microglia, respectively. M1 microglia have a 
flattened, rounded morphology and M2 microglia are more elongated. There were no 
observable changes in microglial morphology over twenty-four hours due to treatment 
with IL-10, LPS, LTA, or PGN (Figures 8, 9, 10, 11). At each time point, the cells 
appeared to have the same rounded morphology as the untreated cells (Figures 8, 9, 10, 
11).  
 
There was no significant difference in /β-tubulin or phalloidin-labeled F-actin 
fluorescent intensity per cell between any experimental group at 6, 12, or 24 hours 
(Appendix Figure 3, Figure 12). However, phalloidin-labeled F-actin intensity of LPS-
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treated cells peaked at 18 hours and was significantly higher than the control, LTA, and 
PGN treatment groups (Figure 12). In general, mean fluorescent intensity appeared 
highest at 18 and 24 hours for LPS, IL-10, LTA, and PGN experimental groups (Figure 
12). 
 
Cell Viability and Cytotoxicity over 24 Hours 
Cell viability was observed and quantified via trypan blue staining and counting with a 
hemocytometer. At six hours, IL-10 treated microglia had a significantly higher percent 
viable cells than LPS, LTA, and PGN treatment groups (Figure 13A-C). By 24 hours, 
LPS-treated microglia had significantly lower percent viable cells than the control 
(Figure 13A-C). Over 24 hours, there was no significant difference in cell viability 
between LTA- and PGN-treated cells and the negative control (Figure 13A-C). 
 
Cell cytotoxicity was quantified via LDH assay. Over 24 hours, the percent cytotoxic 
LPS-treated cells was significantly higher at 6, 18, and 24 hours (Figure 13D-F). 
Although LTA and PGN treatment groups were not significantly different from the 
control at any of the 6 hour time intervals, the percent cytotoxicity of LTA and PGN was 
significantly higher at 18 and 24 hours when compared to the 6 hour experiment (Figure 
13D-F). 
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CONCLUSIONS 
The goal of these experiments was to examine the innate immune response of microglia 
within the first 24 hours of CNS infection by S. aureus. SIM-A9 microglia exposed to 
LTA or PGN did not see a significant decrease in viability nor increase in cytotoxicity 
when compared to controls, suggesting LTA and PGN do not contribute to cytotoxicity 
during the first 24 hours of infection (Figure 13). During S. aureus pathogenesis, 
bacterial toxins such as -hemolysin are predominantly responsible for the observed 
cytotoxicity. Therefore, any changes in microglial cytokine production or cytoskeleton 
organization in these experiments are most likely a result of the cell’s recognition of LTA 
and PGN and not apoptotic signals. 
 
Cytokine expression was examined by ELISA. LTA and PGN exposure progressively 
increased inflammatory cytokine secretion over 24 hours at each time interval (Figure 7). 
Furthermore, PGN consistently induced significantly more TNF- secretion than LTA 
(Figure 7). This suggests PGN is a more potent inducer of inflammatory cytokines than 
LTA, which is supported by previous studies (Kielian et al., 2002). 
 
Treatment of microglia with IL-10 resulted in increased secretion of IL-10 (Appendix 
Figure 1) consistent with the established positive feedback loop of IL-10 signaling 
(Saraiva & O’Garra, 2010). LTA and PGN are known to induce the secretion of IL-10, 
however across triplicate experiments IL-10 production due to LTA and PGN exposure 
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were consistently below the detectable limits of the standard curve and were not 
significantly different than the unstimulated control (Appendix Figure 1). These data 
further suggest LTA and PGN are important inducers of acute S. aureus inflammation. 
 
Cytoskeleton organization over twenty-four hours was observed by fluorescent staining 
of /β-tubulin and F-actin and images were collected under the subjective impression of 
an average 25 cells per field. There were no differences between experimental groups in 
morphology or mean /β-tubulin fluorescent intensity per cell as determined by one-way 
ANOVA (Appendix Figure 2). The only significant detection of increased phalloidin-
labeled F-actin fluorescent intensity was induced by LPS at 18 hours (Figure 11). 
Negative control cells displayed expected M0 morphology and the LTA and PGN 
experimental groups did not appear any different. These results may be due to the 
relatively short experimental time frame. Previous experiments observed changes in 
microglial morphology over 5 days of in vitro LPS and IFN- stimulation (Abd-El-
Basset, Prashanth, & Ananth Lakshmi, 2004). Abd-El-Basset and colleagues (2004) 
reported the majority of cells in a given culture displayed a rounded M1 morphology after 
3 days of LPS stimulation. If these experiments were expanded to 3 – 5 days post-
treatment, we would expect to see a higher occurrence of M1 morphology due to LTA 
and PGN exposure. 
 
  
 
 26 
FUTURE STUDIES 
 To better allow the detection of changes in the highly dynamic structure of the 
cellular cytoskeleton, future experiments should employ the use of real-time microscopy. 
These same experiments could be performed again and a researcher could observe in real 
time the re-arrangements of /β-tubulin and F-actin in a single cell over three to five days 
in living cells. Microglia frequently switch activation states in response to their 
environment. The data from the present study suggest LTA and PGN induce a 
predominantly inflammatory phenotype at six hour time intervals, however, real-time 
microscopy would allow future researchers to detect changes in activation state as the 
immune system tends to modulate inflammation to limit tissue damage in vivo.  
 
In addition to cytoskeletal observations, extending these experiments to a longer 
time frame of three to five days would provide more insights into the TNF- expression 
induced by LTA and PGN exposure. LTA and PGN induced progressively higher TNF- 
expression over twenty-four hours. An extended end time point would allow us to 
determine the time of peak TNF- induction by LTA and PGN. 
 
 Because these experiments were performed in vitro, using an animal model to 
examine the innate response in vivo is the next logical step. Because microglia are 
resident brain macrophages, it is difficult to observe these cells in vitro and expect they 
will behave the same way. Treatments of LTA and PGN in the CNS would provide 
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insight to the potential systemic effects of CNS inflammation and a vehicle through 
which potential novel therapies could be compared. One such therapy could examine 
drugs that allow neutrophils to pass the blood-brain barrier. Neutrophils and dendritic 
cells are among the first to be recruited to the site of an infection and play a crucial role 
in initiating the adaptive response. Novel therapies that help stimulate the adaptive 
response more quickly to clear an infection can work to reduce inflammation in the CNS 
and limit damage to neuronal tissues.  
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FIGURES 
 
 
 
 
Figure 1: Structure of Staphylococcus aureus cell wall. Figure depicts the structure of 
the S. aureus cell wall (adapted from Schröder and colleagues, 2003). Squares represent 
repeating NAG/NAM units of peptidoglycan. Orange circles represent lipoteichoic acid. 
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Figure 2: Recognition of lipoteichoic acid. Figure depicts TLR2 signaling activated by 
S. aureus-derived lipoteichoic acid (adapted from Miller and Cho, 2011). TLR2 is 
activated by the binding of LTA which activates TIRAP and MYD88. This signaling 
cascade produces the activation of NF-B which enters the nucleus and acts as a 
transcription factor to upregulate the expression of inflammatory cytokines and 
chemokines. 
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Figure 3: Recognition of peptidoglycan. Figure depicts NOD2 signaling activated by S. 
aureus-derived peptidoglycan (adapted from Strober and colleagues, 2006). NOD2 is 
activated by the binding of intracellular peptidoglycan. This NOD2 signaling cascade 
produces the activation of NF-B and JNK which enter the nucleus and act as 
transcription factors to upregulate the expression of inflammatory cytokines and 
chemokines. 
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Figure 4: Activation states of microglia. Figure depicts the activation states of 
microglia (adapted from Mosser & Edwards, 2008). M0 recognition of TNF- and IFN- 
result in the M1 inflammatory phenotype, whereas recognition of IL-4 and IL-10 result in 
the M2 anti-inflammatory phenotype. 
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Figure 5: Confirming macrophage cell type with CD11b. Figure shows SIM-A9 
microglia stained for known macrophage marker CD11b (green) viewed under 
fluorescent microscopy. Scale bar represents 50 m. 
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Figure 6: TNF- secretion over 24 hours due to LPS exposure. Figure depicts the 
comparison of TNF- secretion observed at 6, 12, 18, and 24 hours. 6 hour treatment 
represented by white columns. 12 hour treatment represented by light grey columns. 18 
hour treatment represented by dark grey columns. 24 hour treatment represented by black 
columns. Graphs represent the mean of three separate experiments and error bars 
represent the standard error of the mean. No significance between groups as determined 
by one-way ANOVA (p<0.05). 
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Figure 7: TNF-α secretion over 24 hours due to LTA and PGN exposure. Figure 
depicts the comparison of TNF- secretion observed at 6, 12, 18, and 24 hours. 6 hour 
treatment represented by white columns. 12 hour treatment represented by light grey 
columns. 18 hour treatment represented by dark grey columns. 24 hour treatment 
represented by black columns. Graphs represent the mean of three separate experiments 
and error bars represent the standard error of the mean. Significance (*) determined by 
one-way ANOVA (p<0.05).  
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Figure 8: Morphology of SIM-A9 microglia exposed to S. aureus components for 6 
hours compared to known inducers of M1 and M2 phenotypes. Figure depicts 
microglia viewed under fluorescent microscopy after 6 hours of treatment. Insert depicts 
enlarged image of rounded cell similar to M1 morphology. Cells were stained for /β-
tubulin (green) and F-actin (red). Scale bars represent 50 µm. 
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Figure 9: Morphology of SIM-A9 microglia exposed to S. aureus components for 12 
hours compared to known inducers of M1 and M2 phenotypes. Figure depicts 
microglia viewed under fluorescent microscopy after 12 hours of treatment. Cells were 
stained for /β-tubulin (green) and F-actin (red). Scale bars represent 50 µm. 
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Figure 10: Morphology of SIM-A9 microglia exposed to S. aureus components for 
18 hours compared to known inducers of M1 and M2 phenotypes. Figure depicts 
microglia viewed under fluorescent microscopy after 18 hours of treatment. Insert depicts 
enlarged image of elongated cell similar to M2 morphology. Cells were stained for /β-
tubulin (green) and F-actin (red). Scale bars represent 50 µm. 
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Figure 11: Morphology of SIM-A9 microglia exposed to S. aureus components for 
24 hours compared to known inducers of M1 and M2 phenotypes. Figure depicts 
microglia viewed under fluorescent microscopy after 24 hours of treatment. Cells were 
stained for /β-tubulin (green) and F-actin (red). Scale bars represent 50 µm. 
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Figure 12: Comparison of phalloidin-labeled F-actin fluorescent intensity over 24 
hours. Figure depicts comparisons of /β-tubulin intensity/cell between (A) 6 and 12 
hours treatment, (B) 6 and 18 hours treatment, (C) 6 and 24 hours treatment. 6 hour 
treatment represented by white columns. 12 hour treatment represented by light grey 
columns. 18 hour treatment represented by dark grey columns. 24 hour treatment 
represented by black columns. Graphs represent the mean of three separate experiments 
and error bars represent the standard error of the mean. Statistical significance was 
determined by one-way ANOVA (p<0.05). 
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APPENDIX 
 
 
Appendix Figure 1: IL-10 secretion over 24 hours. Figure depicts IL-10 secretion at 6, 
12, 18, and 24 hours after treatment. Graphs represent the mean of three separate 
experiments and error bars represent the standard error of the mean. No significance 
between IL-10 groups as determined by one-way ANOVA (p<0.05).  
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Appendix Figure 2: TNF- secretion over 24 hours. Figure depicts the comparison of 
TNF- secretion between (A) 6 and 12 hours treatment, (B) 6 and 18 hours treatment, 
(C) 6 and 24 hours treatment, and (D) 6 through 24 hours treatment. 6 hour treatment 
represented by white columns. 12 hour treatment represented by light grey columns. 18 
hour treatment represented by dark grey columns. 24 hour treatment represented by black 
columns. Graphs represent the mean of three separate experiments and error bars 
represent the standard error of the mean. Significance (*) determined by one-way 
ANOVA (p<0.05). 
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Appendix Figure 3: Comparison of /β-tubulin fluorescent intensity over 24 hours. 
Figure depicts comparisons of /β-tubulin intensity/cell between (A) 6 and 12 hours 
treatment, (B) 6 and 18 hours treatment, (C) 6 and 24 hours treatment. 6 hour treatment 
represented by white columns. 12 hour treatment represented by light grey columns. 18 
hour treatment represented by dark grey columns. 24 hour treatment represented by black 
columns. Graphs represent the mean of three separate experiments and error bars 
represent the standard error of the mean. Statistical significance was determined by one-
way ANOVA (p<0.05). There was no significant difference in /β-tubulin intensity 
between treatment groups over 24 hours. 
